AstraZeneca to invest $3.5 billion in the United States

British-Swedish drugmaker AstraZeneca plans to invest $3.5 billion in the United States by the end of 2026 to expand the company's research and manufacturing footprint.

The investment includes a new R&D center in Cambridge, Massachusetts, a biologics manufacturing facility in Maryland, and expanded cell therapy production capabilities on the West and East Coasts and specialty products in Texas.

AstraZeneca CEO Pascal Soriot said: "Our multi-billion dollar investment reflects the attractiveness of the U.S. business environment and the quality of its talent and innovation. By expanding our R&D and manufacturing footprint, we aim to strengthen the development of cutting-edge therapies and support U.S. leadership in medical innovation."

AstraZeneca said the planned investments in the United States are part of its goal of achieving $80 billion in total revenue by 2030. AstraZeneca said the United States is its largest market, contributing 44% of its total revenue.